SPDR Select Sector Fund - Health Care News Headlines

(ETF)
XLV 
$70.49
*  
1.31
1.82%
Get XLV Alerts
*Delayed - data as of Aug. 31, 2015  -  Find a broker to begin trading XLV now


Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
ETF Details
Summary Quote ETF Detail Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
ETF NEWS
ETF Headlines Market Stream
FUNDAMENTALS
Short Interest Dividend History
 Save Stocks
Viewing
Filtered By
Ordered By

Pfizer Gets Antitrust Approval to Purchase Hospira
8/31/2015 4:57:00 PM - Market Realist


Fed Watch: Look for Rate Liftoff Cues
8/31/2015 2:29:00 PM - Market Realist




The Trader's Paradise Is The Investor's Nightmare
8/31/2015 6:30:00 AM - Seeking Alpha


AstraZeneca’s Profitability for 2Q15
8/29/2015 12:07:00 AM - Market Realist


Are You Selling The Drama Or Buying The Rally?
8/27/2015 5:53:00 PM - Seeking Alpha




An Analysis of AstraZeneca’s Growth Rate
8/25/2015 7:33:00 PM - Market Realist




Is It Safe?
8/25/2015 8:51:00 AM - Seeking Alpha




Shares of XLV Now Oversold
8/24/2015 12:42:30 PM - BNK Invest










A Bear Market Has 2 Phases
8/19/2015 4:20:00 PM - Seeking Alpha




Pfizer’s Revised Financial Guidance for 2015
8/18/2015 7:05:00 PM - Market Realist


XLV, KRU: Big ETF Outflows
8/17/2015 10:47:44 AM - BNK Invest


What’s in Pfizer’s Product Pipeline?
8/16/2015 8:06:00 AM - Market Realist


Pfizer’s Revenue Falls by 7% in 2Q15
8/14/2015 10:06:00 AM - Market Realist


Pfizer Products with Negative 2Q15 Growth
8/13/2015 6:06:00 PM - Market Realist


What Contributed to Pfizer’s Growth in 2Q15?
8/13/2015 6:06:00 PM - Market Realist


Pfizer’s Improving Growth Rate in 2Q15
8/12/2015 10:00:00 PM - Market Realist